Intellia Therapeutics
Trade Intellia Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About NTLA
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.
NTLA Key Statistics
Stock Snapshot
As of today, Intellia Therapeutics(NTLA) shares are valued at $13.82. The company's market cap stands at 1.63B, with a P/E ratio of -3.51.
During the trading session on 2026-03-09, Intellia Therapeutics(NTLA) shares reached a daily high of $14.04 and a low of $12.92. At a current price of $13.82, the stock is +7.0% higher than the low and still -1.5% under the high.
Trading volume for Intellia Therapeutics(NTLA) stock has reached 1.87M, versus its average volume of 5.19M.
Over the past 52 weeks, Intellia Therapeutics(NTLA) stock has traded between a high of $28.25 and a low of $5.90.
Over the past 52 weeks, Intellia Therapeutics(NTLA) stock has traded between a high of $28.25 and a low of $5.90.
NTLA News
Key Points Intellia Therapeutics is getting around a recent major regulatory setback. However, the stock still faces several potential issues. 10 stocks we l...
The FDA’s decision to lift the clinical hold on Intellia Therapeutics (NTLA) MAGNITUDE Phase 3 trial and the new hereditary angioedema data for lonvoguran ziclu...
If you are wondering whether Intellia Therapeutics is priced attractively today, the key question is how its current share price lines up with the value implied...
Analyst ratings
54%
of 24 ratingsMore NTLA News
RBC Capital raised the firm’s price target on Intellia Therapeutics (NTLA) to $15 from $9 but keeps a Sector Perform rating on the shares. The firm cites the co...
Intellia Therapeutics (NTLA) announced details about its presentation of four posters at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meetin...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.